Skip to main content

VBI Buys 454 GS-FLX Sequencer; Will Enable Institute to 'Tackle Whole Genomes'

NEW YORK (GenomeWeb News) — The Virginia Bioinformatics Institute at Virginia Tech has installed a 454 GS-FLX sequencer at its core lab, the Institute said today.
VBI said installing the 454 sequencer will enable its researchers to sequence 100 megabases in 7 hours, and will be able to achieve lengths of as many as 200 base pairs.
Core lab manager Clive Evans said the GS-FLX will help the institute offer the ability to “tackle whole genomes.”
VBI, located in Blacksburg, Va., focuses on what it calls the “’disease triangle” of host-pathogen-environment interactions in plants, humans, and other animals.”
The core lab provides “various high-throughput technologies” and analysis platforms for DNA sequencing and genotyping, gene expression analysis, and proteomics, VBI said.
Otto Folkerts, associate director of technology development at VBI, said, the institute also is excited about new applications that will be coming along for the sequencer, including “sequencing for transcriptomes, clinical samples, paired-end amplicon sequencing and other cutting edge uses” for the sequencer and its related services. Folkerts said these upcoming applications “dovetail well with our current platforms.”

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.